

Contents

Foreword	ix		
Preface	x		
Introduction	xii		
Perspectives			
<i>Elizabeth H. Blackburn</i>			
Reconciling stress and cancer: insights from telomeres	77		
<i>Cesar G. Victora</i>			
Early-life exposures, birth cohorts, and noncommunicable diseases (with special reference to cancer)	177		
<i>Harald zur Hausen</i>			
Prenatal infections with subsequent immune tolerance could explain the epidemiology of common childhood cancers	261		
<i>Mel Greaves</i>			
An evolutionary foundation for cancer control	337		
<i>Walter C. Willett</i>			
Diet, nutrition, and cancer: where next for public health?	432		
<i>Barnett S. Kramer</i>			
Controversies in cancer screening and their resolution: a view from the United States “battleground”	522		
<i>Richard Peto</i>			
The full hazards of smoking and the benefits of stopping: cancer mortality and overall mortality	586		
1 Cancer worldwide			
1.1 The global and regional burden of cancer	16		
1.2 Transitions in human development and the global cancer burden	54		
1.3 Childhood cancer	69		
2 Cancer etiology			
2.1 The global tobacco epidemic	82		
2.2 Tobacco smoking and smokeless tobacco use	88		
<i>Genetic susceptibility to tobacco-related cancers</i>			
2.3 Alcohol consumption	96		
2.4 Infections	105		
<i>Inflammation and cancer</i>			
<i>Do infections play a role in breast cancer?</i>			
2.5 Reproductive and hormonal factors	115		
2.6 Diet, obesity, and physical activity	124		
<i>Challenges of measuring diet in cancer epidemiological studies and new perspectives</i>			
<i>Single-nucleotide polymorphisms relevant to meat consumption and cancer risk</i>			
<i>Diet and the gut microbiome</i>			
2.7 Occupation	134		
<i>Evaluating carcinogens: dioxins and dioxin-like substances</i>			
<i>Preventing occupational cancer: successes and failures</i>			
2.8 Radiation: ionizing, ultraviolet, and electromagnetic	143		
<i>An IARC announcement that made waves</i>			
2.9 Pollution of air, water, and soil	151		
<i>Bisphenol A and cancer</i>			
<i>Pesticides and cancer</i>			
2.10 Pharmaceutical drugs	161		
<i>Breast implants and cancer</i>			
2.11 Naturally occurring chemical carcinogens	169		
3 Cancer biology			
3.1 Genomics	184		
<i>TP53 mutations and human cancer</i>			
3.2 Genome-wide association studies	193		
<i>Gene–environment interactions and breast cancer</i>			
<i>DNA repair polymorphisms and human cancer</i>			
3.3 Gene expression	203		
<i>Therapeutic implications of dysregulated DNA damage signalling</i>			
3.4 Epigenetics	214		
<i>The non-coding RNA revolution in medical research</i>			
<i>Causes and consequences of microRNA dysregulation in cancer</i>			
3.5 Metabolic change and metabolomics	222		
3.6 Stem cells and cancer stem cells	228		
<i>Stem cells in cancer: determinants of clinical outcome?</i>			
3.7 Tumour microenvironment	236		
3.8 Signal transduction and targeted therapy	244		
3.9 Immunology and immunotherapy	253		
<i>Role of the innate and acquired immune systems in mammary development and breast cancer</i>			
<i>Premortem autophagy and endoplasmic reticulum stress as immunogenic signals in cancer therapy</i>			

4 Cancer prevention			
4.1 Changing behaviours – tobacco control	268		
<i>Australia's plain packaging of tobacco products</i>			
<i>Tobacco and China</i>			
4.2 Changing behaviours – physical activity and weight control	281		
<i>Energy restriction, age, and cancer risk</i>			
<i>EPIC as a model study vehicle</i>			
4.3 Designing and evaluating population-wide campaigns	290		
4.4 Prevention strategies common to noncommunicable diseases	298		
<i>The global economics of chronic and noncommunicable diseases</i>			
4.5 Legislative and regulatory initiatives	305		
<i>Environmental pollution: old and new</i>			
<i>Taxing sugar-sweetened beverages: the Brazilian case</i>			
4.6 Vaccination	314		
<i>Early implementation and monitoring of HPV vaccination in Bhutan</i>			
<i>Introduction and monitoring of a national HPV vaccination programme in Rwanda</i>			
4.7 Screening – principles	322		
4.8 Screening – implementation	330		
5 Cancer by organ site			
<i>A guide to the epidemiology data in World Cancer Report</i>	348		
5.1 Lung cancer	350		
<i>Earliest molecular evidence of tobacco-induced injury in the airway</i>			
<i>Biomarkers of air pollution</i>			
5.2 Breast cancer	362		
<i>Biological mechanisms mediating reduced breast cancer risk through physical activity</i>			
<i>Treatment determined by BRCA1/2 mutation</i>			
5.3 Oesophageal cancer	374		
<i>Risk of malignant progression in Barrett oesophagus patients</i>			
5.4 Stomach cancer	383		
<i>Gastric cancer prevention</i>			
5.5 Colorectal cancer	392		
<i>Lgr5 stem cells in self-renewal and intestinal cancer</i>			
<i>Tumour-elicited inflammation and malignant progression in colorectal cancer</i>			
5.6 Liver cancer	403		
<i>Treating chronic hepatitis with antiviral drugs to prevent liver cancer</i>			
5.7 Pancreatic cancer	413		
5.8 Head and neck cancers	422		
5.9 Kidney cancer	436		
5.10 Bladder cancer	444		
5.11 Cancers of the male reproductive organs	453		
5.12 Cancers of the female reproductive organs	465		
5.13 Haematopoietic and lymphoid malignancies	482		
<i>Molecular detection of minimal residual disease in childhood leukaemia</i>			
<i>De novo DNA methyltransferases in normal and malignant haematopoiesis</i>			
5.14 Skin cancer	495		
<i>Evaluating sunscreen as a measure to reduce the risk of melanoma</i>			
5.15 Thyroid cancer	503		
5.16 Tumours of the nervous system	511		
<i>Glioma genomics and its implications in neuro-oncology</i>			
6 Cancer control			
6.1 National cancer control plans	529		
6.2 Current global national cancer control capacity	538		
<i>Cervical cancer prevention in six African countries</i>			
<i>Traditional household cooking: risks and prevention</i>			
6.3 Health systems strengthening for cancer control	547		
<i>Towards understanding the economics of cancer: priority areas for research</i>			
6.4 Research infrastructure – biobanks, cohorts, registries, and data linkage	554		
6.5 Advocacy for cancer control	562		
6.6 Law in cancer control	569		
6.7 The global economic burden of cancer	576		
Cancer control experiences			
<i>Cancer control in Africa: options for a vulnerable continent</i>	528		
<i>Cancer control in Canada: challenges and strategies in a high-income country</i>	537		
<i>Cancer control in China: preventive policies and accessible health care</i>	546		
<i>Cancer control in France: towards patient-centred precision medicine</i>	553		
<i>Cancer control in India: cancer care through a four-tier system</i>	561		
<i>Cancer control in Jordan: goals for low- and middle-income countries</i>	568		
<i>Cancer control in Morocco: action in harmony with the socioeconomic and cultural context</i>	575		
<i>Cancer control in Peru: “El Plan Esperanza” – the Hope Plan</i>	584		
<i>Cancer control in Turkey: an encouraging national cancer control plan for the future</i>	585		
Contributors	596		
Disclosures of interests	606		
Sources	608		
Subject index	619		